The treatment of dermatophytosis: Safety considerations

Journal of the American Academy of Dermatology

Volumn 43, Issue 5 SUPPL., 2000, Pages

  Smith, Edgar B ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BUTENAFINE; CICLOPIROX; CLOTRIMAZOLE; CYTOCHROME P450; ECONAZOLE; GRISEOFULVIN; KETOCONAZOLE; MICONAZOLE; NAFTIFINE; ORAL CONTRACEPTIVE AGENT; OXICONAZOLE; PHENOBARBITAL; SULCONAZOLE; TERBINAFINE; WARFARIN;

ALLERGIC REACTION; ANAPHYLAXIS; CONTACT DERMATITIS; DERMATOMYCOSIS; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA MULTIFORME; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; LEUKOPENIA; NEPHROSIS; NONHUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; RASH; REVIEW; TERATOGENICITY; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 0033755019     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.110379     Document Type: Article

References (57)

1. History of antifungals
2. Contact allergy to imidazoles used as antimycotic agents
3. Contact dermatitis due to cyclopyroxolamine
4. Allergic contact dermatitis to naftifine. Report of two cases
5. Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris
6. Contact allergy to sodium sulfite contained in an antifungal preparation
7. Propylene glycol allergy from ketoconazole cream
8. Sensitization to benzyl alcohol: A possible cause of 'corticosteroid allergy.'
9. Allergic contact dermatitis due to topical imidazole antimycotics. The sensitizing ability of active ingredients and cross-sensitivity
10. Contact sensitivity to miconazole with ortho-chloro cross-sensitivity to other imidazoles
11. The actions and interactions of drugs: The therapeutic significance of enzyme induction
12. Early forms of porphyria cutanea tarda: Apropos of 2 cases with a study of familial enzymatic deficiency and definition of the mode of genetic transmission
13. The effects of griseofulvin on porphyria cutanea tarda
14. The effect of griseofulvin in hereditary porphyria cutanea tarda
15. Hepatic injury associated with ketoconazole therapy: Analysis of 33 cases
16. Ketoconazole-associated hepatic injury: A clinicopathological study of 55 cases
17. Hepatic reactions associated with ketoconazole in the United Kingdom
18. Systemic antifungal agents: Drug interactions of clinical significance
19. Cyclosporin and ketoconazole, drug interaction or therapeutic association?
20. The role of tacrolimus in adult kidney transplantation: A review
21. Peripheral edema due to nifedipine-itraconazole interaction: A case report
22. Fluconazole-induced symptomatic phenytoin toxicity
23. Oral azole drugs as systemic antifungal therapy
24. Anaphylactic reactions to ketoconazole
25. Imidazole fungicides provoke histamine release from mast cells and induce airway obstruction
26. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole
27. Evaluation of hepatic injury arising during fluconazole therapy
28. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity
29. Itraconazole-induced acute generalized exanthemic pustulosis
30. Itraconazole-induced acute hepatitis
31. Adverse events associated with itraconazole in 189 patients on chronic therapy
32. Debilitating edema associated with itraconazole therapy
33. Peripheral edema due to nifedipine-itraconazole interactions: A case report
34. Pustular psoriasiform eruption with leukocytosis associated with terbinafine
35. Severe pustular psoriasis provoked by oral terbinafine
36. Terbinafine-induced lupus erythematosus
37. Terbinafine and fixed drug eruption
38. Investigation of terbinafine as a CYP2D6 inhibitor in vivo
39. Nortriptyline intoxication induced by terbinafine
40. Overdose of nortriptyline during treatment with terbinafine (1st reported case)
41. Postmarketing surveillance of oral terbinafine in the UK: Report of a large cohort study
42. Safety of oral terbinafine: Results of a postmarketing surveillance study in 25,884 patients
43. Severe neutropenia associated with oral terbinafine therapy
44. The development of green vision in association with terbinafine therapy
45. Taste loss to terbinafine: A case-control study of potential risk factors
46. Hepatitis associated with terbinafine therapy: Three case reports and a review of the literature
47. Cholestatic jaundice due to terbinafine
48. Risk/benefit ratio of modern antifungal therapy: Focus on hepatic reactions